Indeed, chemical modulators for Cdc42, LIMK1, and GSK3β are currently available (Hong et al., 2013; Petrilli et al., 2014) and several FDA-approved GSK3β inhibitors are already being used in the treatment of neurological diseases (Caracci et al., 2016). The gene discussed is GSK3B; the disease is nervous system disorder.